FDA Releases Guidance for Industry on Irritable Bowel Syndrome Clinical Evaluation of Drugs for Treatment

Summary

The US Food and Drug Administration (FDA) has made available a new guidance document to help pharmaceutical companies and researchers develop effective treatments for irritable bowel syndrome (IBS), a condition characterized by recurring abdominal pain and changes in bowel movements, by outlining the use of patient-reported outcome measures as primary endpoints in clinical trials.